EGFR and cancer: In this light, the activation of TRPV1 in the presence of PI3K/Akt and Ras/Raf/MEK/ERK pathway inhibitors—potentially including P2Y2 and EGFR antagonists—may promote cancer cell apoptosis through [Ca2+]i signaling without the induction of proliferative mechanisms.